SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and chronic heart failure with reduced ejection fraction (HFrEF).